Charts

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the fourth quarter and full-year ended December 31, 2022 on Friday, March 31, 2023, after the close of U.S. markets. Following the announcement, the Comp

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disor

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will host a virtual R&D Event on Wednesday, March 22, 2023 at 11:00 am ET.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today provided an interim update from the dose escalation portion of its '501' bioequivalence study of IkT-001Pro, the Company's prodrug formulation of imatinib mesylate designed to enhance the safety and effica

Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of ...

The FDA lifted the full Clinical Hold onInhibikase Therapeutics Inc's(NASDAQ: IKT) IkT-148009, the company's ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the U.S. Food and Drug Administration ("FDA" or "Agency") has lifted the full Clinical Hold on IkT-148009, the Company's c-Abl inhibitor, in Multiple System Atrophy (MSA) allowing the Company to

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit. The event is being held in San F

The Atlanta-based pharmaceutical company raised $10 million to develop treatments related to Parkinson’s Disease and chronic myelogenous leukemia.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has closed its previously announced registered direct offering for the issuance and sale of 6,744,187 of its shares of common stock (or common stock equivalents) at a purchase pric

Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $2.90. MicroAlgo recently entered into securities purchase agreement ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Chevron (CVX) stock is on the rise Thursday following a new share buyback program and dividend for investors, as well as upcoming earnings. The post Why Is Chevron (CVX) Stock Up Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Southwest Airlines (LUV) stock is falling on Thursday following a massive $800 million hit to its net income in Q4 2022. The post LUV Stock Alert: Southwest Reports $800 Million Loss During Holiday Mishap appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inhibikase Therapeutics (IKT) stock is falling on Thursday after the company announced a registered direct offering and private placement. The post Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with an overview of the biggest pre-market stock movers that traders need to watch on Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into definitive agreements for the issuance and sale of 6,744,187 of its shares of common stock (or common stock equivalents) at a purchase price of $0.86 per share (or

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the publication of studies describing the potential of IkT-148009 as a disease-modifying therapy for Parkinson's disease and related disorders. The publication entitled "The c-Abl inhibitor IkT-1

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the U.S. Food and Drug Administration ("FDA" or "Agency") has lifted the full Clinical Hold on IkT-148009 in Parkinson's disease (PD).

Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim ...

According to data from Benzinga Pro, during Q3, Inhibikase Therapeutics's (NASDAQ:IKT) reported sales totaled $7 thousand. Despite a ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the dosing of the first three subjects in its '501' bioequivalence study of IkT-001Pro, the Company's prodrug formulation of imatinib mesylate designed to enhance the safety and efficacy of imati

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or the "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, announced that it has received the U.S. Food and Drug Administration's (FDA) clinical hold letter in regards to the Company's IkT-148009 programs in Parkinson's disease and Multiple System Atrophy.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the Piper Sandler 34th Annual Healthcare Conference being held on November 29 – December 1, 2022, in New Yo

Upgrades According to Janney Montgomery Scott, the prior rating for Consolidated Water Co Ltd (NASDAQ:CWCO) was changed from ...

Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday. Tenax Therapeutics, Inc. ...

Gainers SenesTech, Inc. (NASDAQ: SNES) shares surged 91.7% to $0.2751. SenesTech reported a 1-for-20 reverse stock ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the third quarter ended September 30, 2022 and highlighted recent developments.

The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings. Inhibikase slapped with clinical hold The U.S. Food and Drug Administration has ordered a stop to a Phase 1 trial of a drug made by Inhibikase Therapeutics Inc. (Nasdaq: IKT), which has offices in Lexington.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, after the close of U.S. markets. Following the announcement, the Company will ho

Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) shares jumped 66.5% to settle at $29.10 on Monday amid recent reports ...

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 400 points on Monday. The Dow traded up 1.24% ...

Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. Veru Inc. (NASDAQ: VERU) shares jumped 47% ...

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Monday. The Dow traded up 0.68% ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company was informed via e-mail communication that the U.S. Food and Drug Administration (FDA) has reviewed its Investigational New Drug (IND) application for IkT-148009 for the treatmen

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets: Drug Discovery for Brain and Nerve-Relat

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the Grand Challenges in Parkinson's Disease Conference. The event is being held in Grand Rapids, Michigan and virt

Gainers American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT) climbed 156.3% to close at $0.3750 on Monday. American Virtual ...

Gainers Advanced Human Imaging Limited (NASDAQ: AHI) shares jumped 53% to $1.04. Advanced Human Imaging announced Sunday it signed ...

Gainers NewAge, Inc. (NASDAQ: NBEV) shares rose 19.7% to $0.2432 in pre-market trading. NewAge recently received Nasdaq notice on ...

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ: INCY) Pemazyre(pemigatinib), a selective ...

The U.S. Food and Drug Administration (FDA) has reviewed Inhibikase Therapeutics’ (NASDAQ: IKT) Investigational New Drug (IND) ...

Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the ...

Gainers Sunrise New Energy Co. Ltd. (NASDAQ: EPOW) shares jumped 118.2% to $4.4948. Sunrise New Energy said that the company ...

Inhibikase Therapeutics (NASDAQ:IKT) reported its Q2 earnings results on Friday, August 12, 2022 at 04:00 PM. Here's ...

Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per ...

Inhibikase Therapeutics (NASDAQ:IKT) is set to give its latest quarterly earnings report on Friday, 2022-08-12. Here's ...

Gainers Boxed, Inc. (NYSE: BOXD) rose 38.3% to $1.95 in pre-market trading. Boxed reported that Director Andrew Pearson bought ...

Inhibikase Therapeutics (NASDAQ:IKT) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need ...

Here at CryptocurrenciesChannel. om, we find it interesting to track various ETF and stock prices versus various digital assets over time.

Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at ...

Inhibikase Therapeutics (NASDAQ:IKT) brought in sales totaling $1.94 million during Q4 according to data provided by Benzinga Pro. ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx Says FDA Committee ...

Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth ...

Inhibikase Therapeutics (NASDAQ:IKT) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J, ViiV Co-developed ...

The upcoming trial results are expected to show an excellent safety profile of the drug and perhaps some biomarkers that translate into efficacy.

Biotech stocks reversed course in the week endingMarch 25, as an increase in risk appetite prompted traders to move money out of ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lexicon Clinches Deal to ...

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news ...

Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Inhibikase Therapeutics Inc(NASDAQ: IKT) hasannounced interim three-month resultsfrom its ongoing chronic ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

TheFDA has signed offInhibikase Therapeutics Inc's(NASDAQ: IKT) Phase 1b extension study to evaluate its lead ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...